{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-193913","form_type":"8-K","ticker":"SPRO","cik":"0001701108","company_name":"Spero Therapeutics, Inc.","filed_at":"2024-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.162589+00:00","generated_at":"2026-05-31T13:09:21.767709+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Spero Therapeutics Q2 net loss $17.9M; CMO departs; SPR720 data expected 4Q 2024","bullets":["Net loss $17.9M ($0.33/share) vs $11.9M loss ($0.23) in Q2 2023; revenue $10.2M up from $2.7M.","Cash $63.5M as of June 30, 2024; runway into late 2025 reaffirmed.","SPR720 Phase 2a NTM-PD trial enrollment completed; preliminary data expected 4Q 2024.","CMO Kamal Hamed departing Aug 29; Board member John Pottage appointed Special Advisor to oversee medical function.","Tebipenem HBr Phase 3 PIVOT-PO enrollment on track; target ~2,648 patients, completion H2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-193913","json":"https://secwatch.observer/filing/0001193125-24-193913.json","markdown":"https://secwatch.observer/filing/0001193125-24-193913.md","text":"https://secwatch.observer/filing/0001193125-24-193913.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701108/000119312524193913/0001193125-24-193913-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701108/000119312524193913/d871341d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T13:09:21.767709+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}